Demyelination

- Claus Andersson, PhD, joins Rewind´s Board of Directors Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised…

- Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing first-in-class treatments for…

- Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing first-in-class treatments for…

It results in a range of incapacitating symptoms that differ from one person to another such as The exact causal mechanism is still unclear with no complete cure of the disease. The progressing research towards the sequence of the…

It results in a range of incapacitating symptoms that differ from one person to another such as The exact causal mechanism is still unclear with no complete cure of the disease. The progressing research towards the sequence of the…